PEN SHAREHOLDER ALERT: Hagens Berman, National Trial Attorneys, Continues Penumbra (PEN) Fraud Investigation In Light Of Company’s Admissions, Encourages Investors to Contact its Attorneys Now

The investigation centers on whether Penumbra misled investors about the companys flagship products for treating ischemic stroke.